June 6, 2007 — Results from an MRI substudy of the ongoing FRALYSE randomized trial, although not statistically significant for most end points, show positive trends that infusion of tissue ...

A new report details the case of a patient on the new experimental Alzheimer's drug, lecanemab, who died after experiencing numerous acute intracerebral hemorrhages during treatment with tissue ...

Administered slowly, low-dose infusions of tissue plasminogen activator (tPA) are associated with low mortality and high treatment success rates in patients with obstructive prosthetic valve ...

CHICAGO, IL—Low-dose coronary alteplase infused early after PCI does not reduce the likelihood of microvascular obstruction (MVO) in ST-segment elevation MI, the T-Time trial suggests. Colin Berry, MD ...

Thrombolytic therapy for ischemic stroke with tissue plasminogen activator (tPA) increases the risk of brain hemorrhage. In a Nature Medicine paper, Cheng et al. report that, in rodents, activated ...

Despite probable higher rates of recanalization with endovascular therapies, limited evidence exists to support the clinical benefits in patients with stroke who are unresponsive to standard ...

DALLAS, Feb. 1, 2024 — Compared with the standard clot-busting medication alteplase, the newer clot-buster tenecteplase may offer a safe, effective and simpler way to treat ischemic (clot-caused) ...

LOS ANGELES -- Tenecteplase (TNKase) used off-label as the routine standard for stroke thrombolysis at one Texas stroke network was both feasible and safe, according to the early experience switching ...

Researchers at the University of Oslo are proposing a novel treatment for stroke that involves administering an infusion of a blood protein suspected to protect the brain from damage. Early tests in ...

BERWYN, Pa.--(BUSINESS WIRE)--AscellaHealth, a national specialty pharmacy benefit manager (SPBM) serving commercial, Medicare and Medicaid segments, is collaborating with Group & Pension ...